TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of hemoglobin concentration from baseline to the end of 4th and 6th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference of hemoglobin concentration between experimental and placebo group at the end of 4th and 6th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin concentration change from baseline to the end of first stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin concentration change from baseline to evaluation periods in the second stage (39th ~46th week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HRS incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinical safety laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Medically Significant Wheezing
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects achieving a 4 - fold rise in RSV F antibody titer measured by ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of SPR719
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration (Tmax) of SPR719
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Zero to Tau (AUC0-tau) for SPR719
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Traction forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ottawa bowel preparation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Simple Disease Activity Index (SDAI) Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible radiological signs of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of diaphragmatic paresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with documented use of aspirin or other antithrombotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients who had a fasting lipoprotein (LDL) test performed and whose risk-stratified fasting LDL is at or below the recommended low density lipoprotein (LDL) goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the percentage of patients who had a low density lipoprotein (LDL) test who are prescribed a recommended dose of statin based on risk status if indicated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal bone mass changes postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Infant bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change from baseline in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Potassium balance/retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Potassium serum kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of oxygen reactive species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycosylated Hemoglobin (HbA1c) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in MADRS Score at Week 6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportions of wounds that have healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The Incidence of Early Transplant Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: The Incidence of Acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: The Incidence of Chronic GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: One year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival at 5 Years Post-Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free Survival at Five Years Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Incidence of Relapse With Transplant-related Death as the Competing Risk
Endpoint domain: Mortality/survival
Primary endpoint: Safety and Efficacy of HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiotracer uptake in cortical regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 20m shuttle run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blastocyst euploidy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HOOS self assessment questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Motility disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline of Immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electric Activity of the Diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal capillary non-perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of patients receiving recommended cancer screening and preventive care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with insurance continuity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total number of months uninsured
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of frailty index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multi-morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oro pharyngeal leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of prion disease pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood absolute eosinophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Endothelial Cell Count Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical symptoms including duration of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical symptoms including respiratory frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related adverse events evaluated with CTCAE, version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: total sleep time in hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: absolute durations of sleep states in hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: relative durations of sleep states in hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep state change frequency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Ceasing of symptoms of vaginal discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Quality of Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sore Throat Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of significant stenosis in coronary areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of Urinary N-telopeptide (uNTx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in mean number of nocturnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: QR (relative amount)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive Fields Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive Fields Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence and incidence of HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: swelling reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in skin microperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in skin barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Female Sexual Dysfunction Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: International Index of Erectile Function Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Usability and acceptance of the ATI Neurostimulation System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patient Participants That Received a MedViewer Report as Planned
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Contacted Patients That Were Eligible for a Screening Visit and Agreed to Participate in the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Patient Participants That Were Satisfied With Their Discussion With a Provider Participant About Antiretroviral (ART) Adherence Using the MedViewer Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Patient Participants for Whom Provider Participants Reported the MedViewer Report as Being Useful for Promoting a Productive Antiretroviral (ART) Adherence Discussion
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of Participants Achieving Hemoglobin A1C (HbA1C) <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Hypoglycemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of hemodynamically-significant stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of vulnerable plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ATD treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental Cost-Effectiveness Ratio (cost per avoided prosthesis change)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to normalization of late night salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Geometric Mean Titres (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rabies virus neutralizing antibody (RVNA) titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in neuropsychological assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Canadian Cardiovascular Society (CCS) Angina Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pressure intensity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin quantity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Raynaud's Phenomenon (RP) attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of RP attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of preterm birth due to preeclampsia
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Recovery -15 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the curve (AUC) from time 0 extrapolated to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time of dosing to last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic value of Flicker Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with appropriate number of retrieved oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of anal cytologic and histologic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of decline in eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Gastric Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: level of oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: First step pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function assessment of the affected foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonic Image Quality Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Image Quality Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Treatment Response on Clinician Administered PTSD Scale for DSM-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Damage to Tumor Epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effect of Electrosurgical Damage on Diagnostic Quality of Lumpectomy Specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: placement stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve (AUC(0-tau))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal clearance (CLr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-HTT-binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Combined Upper Arm Circumference Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKS, International Knee Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants with DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial Community Richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes